TY - JOUR
T1 - Selective enhancement of function of stunned myocardium by increased flow
AU - Stahl, L. D.
AU - Aversano, T. R.
AU - Becker, L. C.
PY - 1986
Y1 - 1986
N2 - Although augmentation of flow does not improve the performance of normal myocardium, the hyperemic response after brief coronary occlusion is associated with transient hyperfunction in the previously ischemic region. In this study we assessed the effect of vasodilator-enhanced coronary blood flow on the systolic function of postischemic stunned myocardium. In 18 open-chest, anesthetized dogs the anterior descending artery was occluded for 5 min, followed by a 10 min period of reflow, repeated 12 times with a final 90 min recovery period. After the recovery period, either 0.06 mg/min dipyridamole (n = 6), 1 mg/min papaverine (n = 6), or 1.5 μg/kg/min nitroglycerin (n = 6) was infused intravenously for 15 min. Regional myocardial blood flow, which had returned to normal before administration of vasodilator, was increased 150% above baseline by dipyridamole and 80% by papaverine, but was unchanged by nitroglycerin. Segmental shortening decreased after repeated occlusions: from 17.5% to 0.9% in the group later treated with dipyridamole, from 18.6% to 6.7% in the papaverine group, and from 19.2 % to -1.9% in the nitroglycerin group ( p < .005 for all groups). Segmental shortening increased to 8.8% after dipyridamole, 13.6% after papaverine, and 5.1% after nitroglycerin (p < .05 for all groups), although the load-independent end-systolic pressure-length relationship (ESPLR) showed a significant shift to the left, reflecting enhanced performance, only after dipyridamole and papaverine. For all dogs combined, the percent improvement in ESPLR was correlated with the percent increase in flow (R = -.73, p < .001). Performance was unchanged in the control region despite similar augmentation of flow. This study demonstrates that the function of postischemic myocardium can be selectively enhanced by augmentation of coronary blood flow to levels greater than normal.
AB - Although augmentation of flow does not improve the performance of normal myocardium, the hyperemic response after brief coronary occlusion is associated with transient hyperfunction in the previously ischemic region. In this study we assessed the effect of vasodilator-enhanced coronary blood flow on the systolic function of postischemic stunned myocardium. In 18 open-chest, anesthetized dogs the anterior descending artery was occluded for 5 min, followed by a 10 min period of reflow, repeated 12 times with a final 90 min recovery period. After the recovery period, either 0.06 mg/min dipyridamole (n = 6), 1 mg/min papaverine (n = 6), or 1.5 μg/kg/min nitroglycerin (n = 6) was infused intravenously for 15 min. Regional myocardial blood flow, which had returned to normal before administration of vasodilator, was increased 150% above baseline by dipyridamole and 80% by papaverine, but was unchanged by nitroglycerin. Segmental shortening decreased after repeated occlusions: from 17.5% to 0.9% in the group later treated with dipyridamole, from 18.6% to 6.7% in the papaverine group, and from 19.2 % to -1.9% in the nitroglycerin group ( p < .005 for all groups). Segmental shortening increased to 8.8% after dipyridamole, 13.6% after papaverine, and 5.1% after nitroglycerin (p < .05 for all groups), although the load-independent end-systolic pressure-length relationship (ESPLR) showed a significant shift to the left, reflecting enhanced performance, only after dipyridamole and papaverine. For all dogs combined, the percent improvement in ESPLR was correlated with the percent increase in flow (R = -.73, p < .001). Performance was unchanged in the control region despite similar augmentation of flow. This study demonstrates that the function of postischemic myocardium can be selectively enhanced by augmentation of coronary blood flow to levels greater than normal.
UR - http://www.scopus.com/inward/record.url?scp=0022485229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022485229&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.74.4.843
DO - 10.1161/01.CIR.74.4.843
M3 - Article
C2 - 3093117
AN - SCOPUS:0022485229
SN - 0009-7322
VL - 74
SP - 843
EP - 851
JO - Circulation
JF - Circulation
IS - 4
ER -